Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Kinder Morgan heads into its October 21 Q3 print having already delivered the number once: an October 14 preliminary release moved the stock down 1.8% on the day, yet the shares have kept climbing, now up 11% over the past month to $34.20 and 5.3% on the week alone.
The market structure around Wednesday's event is relaxed by any measure. Short interest at 2.1% of the free float is low and has trimmed further over the past week, down roughly 1.7%. Availability is essentially unlimited, with over 7,800% of short interest still available to borrow, meaning the lending market exerts no pressure from either direction. Cost to borrow ticked up 21% over the past week to 0.49%, but that move lands it at less than half a percentage point, nothing that changes the calculus for bears. Options positioning is equally calm: the put/call ratio of 0.51 is barely above its 20-day average of 0.50, a z-score of 0.28, well within neutral territory and far below the 52-week high of 0.87. Neither the short book nor the options market is treating this as a high-conviction event.
The analyst debate sits in the same measured register. The consensus is clustered around neutral, with targets bunched in the $33 to $38 range. RBC lifted its target to $36 in late September while holding Sector Perform, and Wells Fargo holds Overweight with a $36 target. Jefferies trimmed to $33 in September, the contrarian note in an otherwise constructive pack. Analyst recommendation differential scores in the 93rd percentile against peers, a signal that the Street's overall stance is well above the midstream average even if few firms are pounding the table. Bulls point to the growing project backlog, including the Trident Intrastate Pipeline and Mississippi Crossing, plus the data-centre gas supply opportunity as a structural demand driver. Bears flag commodity price sensitivity, re-contracting risk and execution risk on the pipeline build-out. The stock's P/E has expanded roughly 1.5 points over the past month to 22.1x, reflecting the rally rather than a re-rating of estimates.
One structural backdrop worth noting is the CRSP index arithmetic. ORTEX's Index Rebalance Radar puts a 55% probability on KMI being removed from the CRSP US Mega index at the December quarterly review, with $27M of index-tracker selling implied if that comes to pass. At the same time, ORTEX puts the same 55% probability on a share-count increase in the CRSP US Mid index, implying $619M of buying, roughly 1.6 days of normal volume. The price that decides the Mega deletion sits at $34.29, just nine cents above the current close, meaning the stock is effectively on the line heading into the rank date of December 4. Neither row is confirmed, both are forecasts, but the symmetry of the two competing flows gives the December review an unusual amount of mechanical interest.
The October 21 print will test whether the Q3 figures, now formally reported, can justify a stock that has run 19% year to date and is trading within a whisker of the price that determines its index constituency for 2027.
See the live data behind this article on ORTEX.
Open KMI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
